Press Releases Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Real-time Estimate Cboe BZX Other stock markets 08:31:59 10/05/2024 pm IST			5-day change	1st Jan Change
6.435 ^USD	-2.50%		+3.12%	-28.20%

07/05	Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $18 From $15, Maintains Buy Rating	MT
06/05	Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress	10/05	GL
Travere Therapeutics to Present at Upcoming Investor Conferences	09/05	GL
Travere: Q1 Earnings Snapshot	07/05	AQ
Travere Therapeutics Reports First Quarter 2024 Financial Results	07/05	GL
Travere Therapeutics to Report First Quarter 2024 Financial Results	30/04	GL
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI for the treatment of IgA Nephropathy	25/04	AQ
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy	24/04	GL
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy	24/04	PR
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International	05/04	GL
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association	04/04	GL
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	14/03	GL
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	14/03	AQ
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)	11/03	GL
Travere Therapeutics to Present at Upcoming Investor Conferences	27/02	GL
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy	26/02	AQ
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy	23/02	GL
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy	23/02	PR
Travere: Q4 Earnings Snapshot	16/02	AQ
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	16/02	GL
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results	09/02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Press Releases

Filters